Sunshine Biopharma Warrant Stock Profit Margin

SBFMW Stock  USD 0.22  0.01  4.76%   
Sunshine Biopharma Warrant fundamentals help investors to digest information that contributes to Sunshine Biopharma's financial success or failures. It also enables traders to predict the movement of Sunshine Stock. The fundamental analysis module provides a way to measure Sunshine Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sunshine Biopharma stock.
Last ReportedProjected for Next Year
Net Loss(0.19)(0.20)
Gross Profit Margin is likely to climb to 0.36 in 2024, whereas Pretax Profit Margin is likely to drop (0.18) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sunshine Biopharma Warrant Company Profit Margin Analysis

Sunshine Biopharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current Sunshine Biopharma Profit Margin

    
  (0.13) %  
Most of Sunshine Biopharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunshine Biopharma Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sunshine Profit Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Sunshine Biopharma is extremely important. It helps to project a fair market value of Sunshine Stock properly, considering its historical fundamentals such as Profit Margin. Since Sunshine Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sunshine Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sunshine Biopharma's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Sunshine Pretax Profit Margin

Pretax Profit Margin

(0.18)

At this time, Sunshine Biopharma's Pretax Profit Margin is fairly stable compared to the past year.
Based on the latest financial disclosure, Sunshine Biopharma Warrant has a Profit Margin of -0.1282%. This is 98.86% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 89.91% lower than that of the firm.

Sunshine Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.
Sunshine Biopharma is currently under evaluation in profit margin category among its peers.

Sunshine Fundamentals

About Sunshine Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.